Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

Arcus Biosciences Inc. has identified mast/stem cell growth factor receptor Kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, allergy, autoimmune, inflammatory, ...

Depending on where the mast cells have accumulated ... In the last few years, tyrosine kinase inhibitors (called KIT inhibitors) have really transformed treatment of advanced systemic mastocytosis ...

When mast cells accumulate with SM ... Note that this medication is an oral wild-type KIT inhibitor that demonstrated a positive safety profile with dose-dependent effects on the serum tryptase ...

underscoring the importance of treating patients early in the ISM disease course -- -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity ...

Human stroke patient dura and blood was sampled to assess mast cell activity and to identify potential ligands for Mrgprb2 activation. Lastly, we used osthole, a Mrgprb2 inhibitor, as a post-MCAO ...

She added, "mast cell activation, or mast cell hyperactivity ... Symptomatic response to MC activation inhibitors can also be used but isn't required as it is in the other definition.